Inactivated Mesenchymal Stem Cells Maintain Immunomodulatory Capacity.

Area of Science:

• Immunology
• Cell Therapy
• Regenerative Medicine

Background:

• Mesenchymal stem cells (MSC) show promise for immune disease treatment but have safety concerns and unclear mechanisms.
• Understanding MSC therapeutic components is crucial for optimizing treatments and identifying responsive diseases.

Purpose of the Study:

• To investigate the role of MSC secretome and active cell signaling in immunomodulation.
• To identify the key components responsible for MSC therapeutic effects.

Main Methods:

• Generated heat-inactivated MSC (HI-MSC) lacking secretory and response functions.
• Compared biodistribution, persistence, and immunomodulatory effects of HI-MSC and control MSC in mice with ischemic kidney injury and sepsis.
• Assessed in vitro T-cell proliferation, regulatory B-cell induction, and monocyte function modulation.

Main Results:

• HI-MSC and control MSC exhibited similar biodistribution and persistence.
• Both HI-MSC and control MSC modulated monocyte function in response to lipopolysaccharides.
• HI-MSC failed to suppress T-cell proliferation or induce regulatory B-cells, unlike control MSC.

Conclusions:

• MSC immunomodulation in certain disease models relies on monocyte recognition, not the secretome or active immune cell crosstalk.
• Findings offer a new perspective on MSC immunomodulation and highlight key therapeutic components.